Dopamine in Clinical Practice
Primary Recommendation
Dopamine should be reserved as a second-line vasopressor in highly selected patients (those with low risk of tachyarrhythmias and absolute or relative bradycardia), while norepinephrine remains the first-choice vasopressor for septic shock. 1 For inotropic support in acute heart failure, dopamine can be used at 3-5 mcg/kg/min, though dobutamine is generally preferred for augmenting cardiac output. 2, 3
Dose-Dependent Effects and Administration
Dopamine exhibits distinct pharmacologic effects based on infusion rate:
2-3 mcg/kg/min: Predominantly dopaminergic receptor stimulation with renal vasodilation, though clinical evidence shows limited effects on diuresis and no renal protection. 2, 1, 3
3-5 mcg/kg/min: Beta-adrenergic stimulation producing inotropic effects with increased myocardial contractility and cardiac output. 2, 3, 4
>5 mcg/kg/min: Progressive alpha-adrenergic stimulation causing vasoconstriction and increased systemic vascular resistance, useful for maintaining blood pressure in hypotensive patients but potentially deleterious by increasing left ventricular afterload and pulmonary pressures. 2, 5, 3
>10 mcg/kg/min: Predominantly vasopressor effects. 4
The FDA-approved regimen recommends starting at 2-5 mcg/kg/min in patients likely to respond to modest increments, or 5 mcg/kg/min in more seriously ill patients, with gradual increases in 5-10 mcg/kg/min increments up to 20-50 mcg/kg/min as needed. 6
Clinical Context: Septic Shock
The Surviving Sepsis Campaign explicitly recommends against using dopamine as a first-line vasopressor. 1 Norepinephrine is the first-choice agent (strong recommendation, moderate quality evidence), with dopamine relegated to an alternative only in highly selected patients with low risk of tachyarrhythmias or bradycardia (weak recommendation, low quality evidence). 1
This downgrade stems from evidence showing dopamine is associated with increased mortality in septic patients and increased arrhythmias compared to norepinephrine. 7 Low-dose dopamine should absolutely not be used for renal protection (strong recommendation, high quality evidence). 1
Clinical Context: Acute Heart Failure
For acute heart failure with peripheral hypoperfusion (hypotension, decreased renal function) refractory to diuretics and vasodilators, inotropic agents including dopamine are indicated. 2, 5
Dopamine at 3-5 mcg/kg/min provides inotropic support, though dobutamine (starting at 2-3 mcg/kg/min, titrated to 15-20 mcg/kg/min) is generally preferred for augmenting cardiac output in chronic low-output cardiac failure. 2, 3 The European Society of Cardiology gives dopamine a Class IIb recommendation (level of evidence C) for this indication. 2
For patients with systolic blood pressure <90 mmHg, dopamine may be considered; for systolic blood pressure 90-100 mmHg, dobutamine or a vasodilator/inotrope combination is preferred. 3
Administration and Monitoring Requirements
Dopamine must be infused through a large vein whenever possible (antecubital fossa preferred over hand or ankle veins) because extravasation causes severe tissue necrosis and sloughing. 6 Central venous access is preferred, though peripheral large-bore or intraosseous access can be used if central access is unavailable or staff experience is limited. 8
Use only an infusion pump, preferably volumetric, not gravity-regulated apparatus. 6 Continuous monitoring requirements include:
- Blood pressure (invasive arterial catheter placement recommended as soon as practical for all patients requiring vasopressors) 1, 4
- Heart rate and continuous ECG telemetry 3, 4
- Urine output (should urinary flow decrease without hypotension, reduce dopamine dosage) 6
- Signs of organ perfusion and congestion 3
- Infusion site for extravasation 8, 6
Blood pressure should be measured every 5-15 minutes during infusion. 8
Critical Warnings and Adverse Effects
Dopamine carries significant risks that limit its clinical utility:
Tachycardia and arrhythmias: Use with extreme caution in patients with heart rate >100 bpm. 2 In cardiogenic shock, patients treated with norepinephrine versus dopamine had improved 28-day survival and fewer arrhythmias. 3
Increased myocardial oxygen demand: Potentially harmful as it increases oxygen consumption and calcium loading. 5
Vasoconstriction at higher doses: Alpha-adrenergic stimulation increases afterload, which may be deleterious in acute heart failure. 2, 5
No renal protection: Despite historical use, low-dose dopamine does not prevent acute kidney injury or improve renal outcomes and should not be used for this purpose. 1, 7, 9, 10, 11
Splanchnic effects: Evidence suggests low-dose dopamine may worsen splanchnic oxygenation and impair GI function. 11
Endocrine and immunologic impairment: Low-dose dopamine may impair endocrine and immune systems and blunt ventilatory drive. 11
Discontinuation Protocol
When discontinuing dopamine, gradually decrease the dose while expanding blood volume with intravenous fluids to prevent marked hypotension. 6 Withdraw inotropic agents as soon as adequate organ perfusion is restored and/or congestion reduced. 3
Key Pitfalls to Avoid
Do not use low-dose dopamine for "renal protection" - this practice is ineffective and potentially dangerous. 1, 7, 10, 11
Do not use dopamine as first-line vasopressor in septic shock - norepinephrine is superior with lower mortality and fewer arrhythmias. 1, 7
Do not administer through small peripheral veins - extravasation causes severe tissue necrosis. 6
Do not combine with alkalinizing substances - dopamine is inactivated in alkaline solution. 6
Do not ignore rising heart rate or new arrhythmias - these are indications to decrease or temporarily suspend dosage. 6
Monitor for disproportionate rise in diastolic pressure (marked decrease in pulse pressure), which indicates predominant vasoconstrictor activity requiring dose reduction. 6